2017
A robust vitronectin-derived peptide for the scalable long-term expansion and neuronal differentiation of human pluripotent stem cell (hPSC)-derived neural progenitor cells (hNPCs)
VARUN, Divya, Gayathri Rajaram SRINIVASAN, Yi-Huan TSAI, Hyun-Je KIM, Joshua CUTTS et. al.Základní údaje
Originální název
A robust vitronectin-derived peptide for the scalable long-term expansion and neuronal differentiation of human pluripotent stem cell (hPSC)-derived neural progenitor cells (hNPCs)
Autoři
VARUN, Divya (840 Spojené státy), Gayathri Rajaram SRINIVASAN (840 Spojené státy), Yi-Huan TSAI (840 Spojené státy), Hyun-Je KIM (840 Spojené státy), Joshua CUTTS (840 Spojené státy), Francis PETTY (840 Spojené státy), Ryan MERKLEY (840 Spojené státy), Nicholas STEPHANOPOULOS (840 Spojené státy), Dáša DOLEŽALOVÁ (703 Slovensko, garant, domácí), Martin MARSALA (840 Spojené státy) a David A. BRAFMAN (840 Spojené státy)
Vydání
Acta Biomaterialia, Oxford, Elsevier BV, 2017, 1742-7061
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30200 3.2 Clinical medicine
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 6.383
Kód RIV
RIV/00216224:14110/17:00095986
Organizační jednotka
Lékařská fakulta
UT WoS
000393247000010
Klíčová slova anglicky
Human pluripotent stem cells; Human neural progenitor cells; Peptide; Defined conditions
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 15. 3. 2018 17:18, Soňa Böhmová
Anotace
V originále
Despite therapeutic advances, neurodegenerative diseases and disorders remain some of the leading causes of mortality and morbidity in the United States. Therefore, cell-based therapies to replace lost or damaged neurons and supporting cells of the central nervous system (CNS) are of great therapeutic interest. To that end, human pluripotent stem cell (hPSC) derived neural progenitor cells (hNPCs) and their neuronal derivatives could provide the cellular ‘raw material’ needed for regenerative medicine therapies for a variety of CNS disorders. In addition, hNPCs derived from patient-specific hPSCs could be used to elucidate the underlying mechanisms of neurodegenerative diseases and identify potential drug candidates. However, the scientific and clinical application of hNPCs requires the development of robust, defined, and scalable substrates for their long-term expansion and neuronal differentiation. In this study, we rationally designed a vitronectin-derived peptide (VDP) that served as an adhesive growth substrate for the long-term expansion of several hNPC lines. Moreover, VDP-coated surfaces allowed for the directed neuronal differentiation of hNPC at levels similar to cells differentiated on traditional extracellular matrix protein-based substrates. Overall, the ability of VDP to support the long-term expansion and directed neuronal differentiation of hNPCs will significantly advance the future translational application of these cells in treating injuries, disorders, and diseases of the CNS.